No Data
Express News | Four CAR-T 'expensive drugs' did not enter the new version of the national medical insurance catalog.
The National Medical Insurance Administration: Negotiated pharmaceuticals during the agreement period have reduced the financial burden on patients by over 880 billion yuan.
This morning, the National Medical Insurance Administration announced the new version of the pharmaceutical catalog at a press conference. A responsible official from the National Medical Insurance Administration stated at the meeting that since its establishment, the speed of new drugs entering the catalog has continuously accelerated, allowing insured individuals to enjoy the benefits brought by pharmaceutical innovation in a timely manner. As of the end of October this year, the cumulative number of beneficiaries from negotiated pharmaceutical products during the agreement period reached 0.83 billion people, alleviating the financial burden on patients by more than 880 billion yuan. With more new drugs entering the catalog, the level of benefits for patients will steadily improve, which will effectively enhance the confidence of the pharmaceutical industry in increasing research and development innovation, conducive to better promoting economic and social development.
This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.
Many innovative drugs stocks in Hong Kong suddenly soared!
On the morning of November 25, the hang seng index fell slightly, while the Hong Kong stock market's biomedical sector performed well. Notably, several biomedical companies saw their stock prices rise significantly due to recent news of major collaboration advancements.
WuXi AppTec (02126): Deloitte appointed as the new auditor.
Wu & Partners has submitted a resignation as the auditor to the board of directors in an announcement released by WuXi AppTec Group (HKG: 02126), effective from 2024...
National Healthcare Security Administration: Negotiations on healthcare will be held in Beijing next week, with adjusted results expected to be announced next month.
According to CCTV, it was learned from the National Medical Insurance Administration that the on-site negotiation/bidding of the medical insurance catalog for 2024 will be held in Beijing from Sunday (the 27th) to next Wednesday (the 30th) as per the work arrangement. The adjustment results are expected to be announced in November, and the new version of the pharmaceutical catalog will be implemented starting next year. According to the "Work Plan for the Adjustment of the National Medical Insurance Pharmaceutical Catalog in 2024", the seventh adjustment of the national medical insurance pharmaceutical catalog since the establishment of the National Medical Insurance Administration officially started in July. After formal review, expert evaluation, and result confirmation, a total of 162 generic pharmaceuticals have been confirmed to participate in negotiations/bidding.
